Detailed Abstract
[BP Poster Presentation 7 - Biliary & Pancreas (Others(ERAS, Education etc.))]
[BP PP 7-4] Clinical Outcome Of Resected Nonampullary Duodenal Adenocarcinoma : A Single Center Experience.
Soo Yeun LIM1 , Dong Il CHUNG2 , Hye Jeong JEONG1 , Hyun Jeong JEON1 , So Jeong YOON1 , Hongbeom KIM1 , In Woong HAN1 , Jin Seok HEO1 , Sang Hyun SHIN*1
1 Division Of Hepatobiliary-pancreatic Surgery, Department Of Surgery, Samsung Medical Center, Sungkyunkwan University School Of Medicine, REPUBLIC OF KOREA
2 Department Of Medicine, Sungkyunkwan University School Of Medicine, REPUBLIC OF KOREA
Background : This study identified the clinical outcome and prognostic factors of resected non-ampullary duodenal adenocarcinoma (NADA) in a single tertiary cancer center.
Methods : The medical records of 109 patients with NADA who underwent curative surgery between 2000 and 2018 were reviewed retrospectively.
Results : The mean age was 62.4 years with a male predominance (70.6%). The majority of tumors were located at the 2nd portion (58.7%). Fifty-seven patients (52.3%) had symptoms at diagnosis. CA19-9 was elevated in 32 patients (29.4%). Of this cohort, most patients were diagnosed as stage III (64.2%). The median overall survival was 92.9 months, and the 1-, 3-, and 5-year survival rates were 84.4%, 71.6%, and 53.7%, respectively. In univariate and multivariate analysis, age, symptoms, CA19-9, and margin status were associated with overall survival and symptoms, CA19-9 and margin status were also associated with recurrence. When correlating symptoms with stages, patients with symptoms at diagnosis had more advanced stages (all p < 0.001).
Conclusions : Old age, elevated CA19-9, symptoms, and margin status were independent prognostic factors of NADA, and the patients with symptoms at diagnosis tend to have more advanced stages and a poor prognosis.
Methods : The medical records of 109 patients with NADA who underwent curative surgery between 2000 and 2018 were reviewed retrospectively.
Results : The mean age was 62.4 years with a male predominance (70.6%). The majority of tumors were located at the 2nd portion (58.7%). Fifty-seven patients (52.3%) had symptoms at diagnosis. CA19-9 was elevated in 32 patients (29.4%). Of this cohort, most patients were diagnosed as stage III (64.2%). The median overall survival was 92.9 months, and the 1-, 3-, and 5-year survival rates were 84.4%, 71.6%, and 53.7%, respectively. In univariate and multivariate analysis, age, symptoms, CA19-9, and margin status were associated with overall survival and symptoms, CA19-9 and margin status were also associated with recurrence. When correlating symptoms with stages, patients with symptoms at diagnosis had more advanced stages (all p < 0.001).
Conclusions : Old age, elevated CA19-9, symptoms, and margin status were independent prognostic factors of NADA, and the patients with symptoms at diagnosis tend to have more advanced stages and a poor prognosis.
SESSION
BP Poster Presentation 7
Poster Presentation 3/24/2023 2:50 PM - 3:50 PM